Sun Pharma gets USFDA nod for generic cardiac drug

Sun Pharmaceutical Industries today said its subsidiary has received approval from the US health regulator to market generic version of GSK's Coreg CR, extended release capsules in the American market. One of the company's wholly-owned subsidiaries has received final approval from US Food and Drug Administration (USFDA) for the generic product



in strengths of 10mg, 20mg, 40mg and 80 mg, Sun Pharma said in a statement.

Coreg CR extended release capsules are indicated for treating various heart conditions, including heart failure and high blood pressure. As per IMS, Coreg CR had annual sales of around USD 208 million in the US for the 12 months ended August 2017.